Russell Investments Group Ltd. boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 2.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 309,498 shares of the biopharmaceutical company’s stock after acquiring an additional 8,183 shares during the period. Russell Investments Group Ltd. owned 0.20% of TG Therapeutics worth $17,264,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of TG Therapeutics during the 2nd quarter valued at $1,211,429,000. Bank of America Corp DE grew its holdings in shares of TG Therapeutics by 71.7% during the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock worth $48,544,000 after purchasing an additional 610,195 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of TG Therapeutics by 129.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock worth $36,029,000 after purchasing an additional 612,068 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth $49,472,000. Finally, Wellington Management Group LLP increased its position in shares of TG Therapeutics by 697.6% in the second quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock worth $26,276,000 after purchasing an additional 418,300 shares during the period. Institutional investors own 58.58% of the company’s stock.
Insider Transactions at TG Therapeutics
In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the transaction, the director owned 168,640 shares in the company, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.87% of the stock is currently owned by corporate insiders.
TG Therapeutics Trading Up 5.4%
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.01). The business had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million. TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. TG Therapeutics’s quarterly revenue was up 60.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.43 earnings per share. Equities analysts anticipate that TG Therapeutics, Inc. will post 1.10 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the company. Weiss Ratings raised TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, November 4th. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 14th. Zacks Research upgraded shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. B. Riley Financial raised their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, HC Wainwright restated a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $63.00.
Check Out Our Latest Research Report on TGTX
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Read More
- Five stocks we like better than TG Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
